



CLAIMS

1. A compound having Structural Formula III:



III, or pharmaceutically acceptable salts thereof, wherein:



Het is a 5- to 6-membered heteroaryl;

R^1 is H, -CN, halogen, C_1 - C_4 alkyl, -O-(C_3 - C_5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C_1 - C_4 alkyl), wherein when R^1 is not H, -CN or halogen, R^1 is optionally substituted with one or more halogens;

each R^2 is independently hydrogen, halogen or C_1 - C_4 alkyl;

R^3 is H or F;

R^{11} is H or -CH₃;

R^{21} is H, halogen, C_1 - C_4 alkyl, C_3 - C_5 cycloalkyl or 4- to 6-membered heterocycle;


R^{22} is H, halogen, or C_1 - C_2 alkyl;


R^{24} is H, -CN, -(C_1 - C_4 alkyl)-CN, C_1 - C_4 alkyl, -(C_1 - C_4 alkyl)-OH, -(C_1 - C_4 alkyl)-N(R^{241})₂, -(C_1 - C_4 alkyl)-O-(C_3 - C_6 cycloalkyl), -(C_1 - C_4 alkyl)-O-(4- to 6-membered heterocycle) or -(C_1 - C_4 alkyl)-O-(C_1 - C_4 alkyl), wherein:



t is 0 or 1;



u is 0 or 1;

with the proviso that when u is 1, t is 1; and
each R^{241} is independently H or C_1 - C_2 alkyl; and
 R^{25} is halogen, -CN, $-(C_1-C_4 \text{ alkyl})-CN$, C_1 - C_2 alkyl or cyclopropyl.


2. The compound of claim 1, wherein when L-Ar is , Ar is not



3. The compound of claim 1, wherein i) L-Ar is  or  and Ar



4. The compound of claim 3, wherein Ar is



5. The compound of any of claims 1-4, wherein i) R^1 is halogen, -CN or C_1 - C_2 haloalkyl; or ii) R^1 is -CN.

6. The compound of any of claims 1-5, wherein R^2 is H.
7. The compound of any of claims 1-6, wherein i) R^{21} is halogen, C_1 - C_4 alkyl or C_3 - C_5 cycloalkyl; or ii) R^{21} is C_1 - C_4 alkyl or C_3 - C_5 cycloalkyl; or iii) R^{21} is C_1 - C_2 alkyl or C_3 - C_5 cycloalkyl; or iv) R^{21} is C_1 - C_2 alkyl; or v) R^{21} is $-CH_3$.
8. The compound of any of claims 1-7, wherein i) R^{22} is H or C_1 - C_2 alkyl; or ii) R^{22} is H or $-CH_3$; or iii) R^{22} is $-CH_3$.
9. The compound of any of claims 1-8, wherein i) R^{24} is H, $-CN$, $-(C_1-C_4 \text{ alkyl})-CN$, C_1 - C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_6 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4\text{- to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or ii) R^{24} is H, C_1 - C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_6 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4\text{- to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or iii) R^{24} is C_1 - C_4 alkyl or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or iv) R^{24} is $-(C_1-C_2 \text{ alkyl})-O-(C_1-C_2 \text{ alkyl})$; or v) R^{24} is C_1 - C_2 alkyl; or vi) R^{24} is C_3 - C_6 cycloalkyl; or vii) R^{24} is $-CN$ or $-(C_1-C_2 \text{ alkyl})-CN$; or viii) R^{24} is $-(C_1-C_2 \text{ alkyl})-CN$; or ix) R^{24} is methyl, isopropyl, cyclopropyl, $-CN$, or $-(C_1-C_2 \text{ alkyl})-CN$.
10. The compound of claim 9, wherein i) R^{24} is $-CH_2-O-CH_3$; or ii) R^{24} is $-CH_3$; or iii) R^{24} is $-CN$; or iv) R^{24} is H, $-CH_3$, $-CH_2OH$, $-CH_2OCH_3$, $-(CH_2)_2OH$, $-(CH_2)_2OCH_3$ or $-(CH_2)_2N(CH_3)_2$.
11. The compound of claim 9, wherein R^{24} is substituted with one or more substituents selected from C_1 - C_2 alkyl, oxo, $-CN$, halogen, alkanoyl, alkoxycarbonyl, $-OH$ and C_1 - C_2 alkoxy when R^{24} is $-(C_1-C_4 \text{ alkyl})-CN$, C_1 - C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_6 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4\text{- to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or R^{24} is substituted with one or more substituents selected from methyl, $-F$, methoxy, $-C(=O)CH_3$ and $-C(=O)-OCH_3$ when R^{24} is $-(C_1-C_4 \text{ alkyl})-CN$, C_1 - C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_6 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4\text{- to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$.
12. The compound of claim 11, wherein i) R^{24} is substituted with two substituents that

are the same or different when R^{24} is $-(C_1-C_4 \text{ alkyl})-CN$, C_1-C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_6 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4- \text{ to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or ii) R^{24} is substituted with three substituents that are the same or different when R^{24} is $-(C_1-C_4 \text{ alkyl})-CN$, C_1-C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_6 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4- \text{ to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$.


13. The compound of any of claims 1-12, wherein i) R^{25} is halogen, $-CN$, C_1-C_2 alkyl or cyclopropyl; or ii) R^{25} is halogen, C_1-C_2 alkyl or cyclopropyl.

14. The compound of claim 13, wherein i) R^{25} is $-CN$, $-Cl$ or $-CH_3$; or ii) R^{25} is $-Cl$; or R^{25} is $-CH_3$.


15. The compound of any of claims 1-13, wherein when R^{25} includes alkyl or cyclopropyl, i) R^{25} is substituted with one or more substituents selected from $-OH$, halogen, C_1-C_2 alkyl and alkylcarbonyloxy; or ii) R^{25} is substituted with one or more substituents selected from $-F$, methyl and $-O-C(=O)-CH_3$.


16. The compound of claim 15, wherein when R^{25} includes alkyl or cyclopropyl, i) R^{25} is substituted with two substituents that are the same or different; or ii) R^{25} is substituted with three substituents that are the same or different.

17. A compound of Structural Formula IIIb:



IIIb, or pharmaceutically acceptable salts thereof, wherein:





Het is a 5- to 6-membered heteroaryl;

R^1 is H, -CN, halogen, C_1 - C_4 alkyl, -O-(C_3 - C_5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C_1 - C_4 alkyl), wherein when R^1 is not H, -CN or halogen, R^1 is optionally substituted with one or more halogens;

each R^2 is independently hydrogen, halogen or C_1 - C_4 alkyl;

R^3 is H or F;

R^{11} is H or -CH₃;

R^{21} is H, halogen, C_1 - C_4 alkyl, C_3 - C_5 cycloalkyl or 4- to 6-membered heterocycle;

R^{22} is H, halogen or C_1 - C_2 alkyl; and


each R^{24} and R^{25} is independently H, halogen, -CN, -(C_1 - C_4 alkyl)-CN, C_1 - C_4 alkyl, -(C_1 - C_4 alkyl)-OH, -(C_1 - C_4 alkyl)-N(R^{241})₂, -(C_1 - C_4 alkyl)_t-O_u-(C_3 - C_5 cycloalkyl), -(C_1 - C_4 alkyl)_t-O_u-(4- to 6-membered heterocycle) or -(C_1 - C_4 alkyl)_t-O-(C_1 - C_4 alkyl), wherein:

each t is 1;


each u is independently 0 or 1; and



each R^{241} is independently H or C_1 - C_2 alkyl,




wherein the compound is not:




18. The compound of claim 17, wherein when L-Ar is , Ar is not



19. The compound of claim 17, wherein i) L-Ar is  or  Ar and



20. The compound of claim 19, wherein Ar is



21. The compound of any of claims 17-20, wherein i) R¹ is halogen, -CN or C₁-C₂ haloalkyl; or ii) R¹ is -CN.

22. The compound of any of claims 17-21, wherein R² is H.

23. The compound of any of claims 17-22, wherein i) R²¹ is halogen, C₁-C₄ alkyl, C₃-C₅ cycloalkyl or 4- to 6-membered heterocycle; or ii) R²¹ is C₁-C₄ alkyl, C₃-C₅ cycloalkyl or 4- to

6-membered heterocycle; or iii) R^{21} is C_1 - C_2 alkyl or C_3 - C_5 cycloalkyl; or iv) R^{21} is C_1 - C_2 alkyl; or v) R^{21} is $-CH_3$.

24. The compound of any of claims 17-23, wherein i) R^{22} is H or C_1 - C_2 alkyl; or ii) R^{22} is H or $-CH_3$; or iii) R^{22} is $-CH_3$.

25. The compound of any of claims 17-24, wherein i) each R^{24} and R^{25} is independently H, $-CN$, C_1 - C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_5 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4- \text{ to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or ii) each R^{24} and R^{25} is independently H, C_1 - C_4 alkyl, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4- \text{ to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or iii) R^{24} is H, C_1 - C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_5 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4- \text{ to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or iv) R^{24} is $-CN$, $-Cl$, C_1 - C_4 alkyl or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or v) R^{24} is C_1 - C_4 alkyl or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or vi) R^{24} is $-(C_1-C_2 \text{ alkyl})-O-(C_1-C_2 \text{ alkyl})$; or vii) R^{24} is C_1 - C_4 alkyl.

26. The compound of claim 17-25, wherein i) R^{24} is $-CH_3$; or ii) R^{24} is hydrogen.

27. The compound of any of claims 17-25, wherein i) R^{24} is substituted with one or more substituents selected from halogen, C_3 - C_5 cycloalkyl and C_1 - C_2 alkoxy when R^{24} is $-(C_1-C_4 \text{ alkyl})-CN$, C_1 - C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_6 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4- \text{ to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or ii) R^{24} is substituted with one or more substituents selected from $-F$, cyclopropyl and $-OCH_3$ when R^{24} is $-(C_1-C_4 \text{ alkyl})-CN$, C_1 - C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_6 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4- \text{ to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$.

28. The compound of claim 27, wherein i) R^{24} is substituted with two substituents that are the same or different when R^{24} is $-(C_1-C_4 \text{ alkyl})-CN$, C_1 - C_4 alkyl, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_6 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4- \text{ to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or ii) R^{24} is substituted with three substituents that


are the same or different when R^{24} is $-(C_1-C_4 \text{ alkyl})-CN$, $C_1-C_4 \text{ alkyl}$, $-(C_1-C_4 \text{ alkyl})-OH$, $-(C_1-C_4 \text{ alkyl})-N(R^{241})_2$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(C_3-C_6 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ alkyl})_t-O_u-(4- \text{ to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$.

29. The compound of any of claims 17-28, wherein i) R^{25} is halogen, methyl, ethyl or cyclopropyl; or ii) R^{25} is $-CN$, $-Cl$, $C_1-C_4 \text{ alkyl}$, $-(C_1-C_4 \text{ alkyl})_t-O-(C_3-C_5 \text{ cycloalkyl})$ or $-(C_1-C_4 \text{ alkyl})_t-O-(C_1-C_4 \text{ alkyl})$; or iii) R^{25} is $-CN$, $-Cl$, $-CH_3$, $-O-(C_3-C_5 \text{ cycloalkyl})$ or $-O-(C_1-C_2 \text{ alkyl})$; or iv) R^{25} is $-CN$, $-Cl$ or $C_1-C_4 \text{ alkyl}$.

30. The compound of claim 17-29, wherein i) R^{25} is $-CH_3$; or ii) R^{25} is $-Cl$.

31. The compound of any of claims 17-29, wherein when R^{25} includes alkyl, cycloalkyl or heterocycle, i) R^{25} is substituted with one or more halogen; or ii) R^{25} is substituted with one or more $-F$; or iii) R^{25} is substituted by two substituents; or iv) R^{25} is substituted by three substituents.

32. A compound having Structural Formula I or II:





or pharmaceutically acceptable salts thereof, wherein:

L^3 is $-CH_2-$, $-CHR^{50}-$, $-O-$, $-NR^{50}-$, $-NC(O)R^{50}-$ or $-NC(O)OR^{50}-$, wherein R^{50} is $C_1-C_6 \text{ alkyl}$, $C_3-C_5 \text{ cycloalkyl}$, or 4- to 6-membered heterocycle;

n is 1, 2, or 3;

m is 1 or 2 with the proviso that $n+m \geq 3$;





Het is a 5- to 6-membered heteroaryl;

R¹ is H, -CN, halogen, C₁-C₄ alkyl, -O-(C₃-C₅ cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C₁-C₄ alkyl), wherein when R¹ is not H, -CN or halogen, R¹ is optionally substituted with one or more halogens;

each R² is independently hydrogen, halogen or C₁-C₄ alkyl;

R³ is H or F;

R¹¹ is H or -CH₃;


R²¹ is H, halogen, C₁-C₄ alkyl, C₃-C₅ cycloalkyl or 4- to 6-membered heterocycle;



R²² is H, halogen, or C₁-C₂ alkyl; and

R²⁴ is H, C₁-C₄ alkyl, -(C₁-C₄ alkyl)-OH, -(C₁-C₄ alkyl)_t-N(R²⁴¹)₂, -(C₁-C₄ alkyl)_t-O-(C₃-C₅ cycloalkyl), -(C₁-C₄ alkyl)_t-O-(4- to 6-membered heterocycle) or -(C₁-C₄ alkyl)_t-O-(C₁-C₄ alkyl), wherein:

each t is independently 0 or 1; and

each R²⁴¹ is independently H or C₁-C₂ alkyl.





34. The compound of claim 33, wherein Ar is

35. The compound of any of claims 32-34, wherein i) R^1 is halogen, $-CN$ or C_1-C_2 haloalkyl; or ii) R^1 is $-CN$ or C_1-C_2 haloalkyl or iii) R^1 is $-CN$; or iv) R^1 is $-Cl$.

36. The compound of any of claims 32-35, wherein R^2 is H.

37. The compound of any of claims 32-36 wherein i) R^{21} is halogen, C_1-C_4 alkyl, C_3-C_5 cycloalkyl or 4- to 6-membered heterocycle; or ii) R^{21} is H, C_1-C_4 alkyl, C_3-C_5 cycloalkyl or 4- to 6-membered heterocycle; or iii) R^{21} is C_1-C_2 alkyl or C_3-C_5 cycloalkyl; or iv) R^{21} is C_3-C_5 cycloalkyl; or v) R^{21} is C_1-C_2 alkyl.


38. The compound of any of claims 32-37, wherein i) R^{22} is H or C_1-C_2 alkyl or ii) R^{22} is H; or iii) R^{22} is C_1-C_2 alkyl; or iv) R^{22} is $-CH_3$.

39. The compound of any of claims 32-38, wherein i) R^{24} is C_1-C_4 alkyl or $-(C_1-C_4 \text{ alkyl})_t-O-(C_1-C_4 \text{ alkyl})$ or ii) R^{24} is $-(C_1-C_2 \text{ alkyl})_t-O-(C_1-C_2 \text{ alkyl})$.





40. The compound of any of claims 32-39, wherein L^3 is $-N(CH_3)-$.

41. The compound of any of claims 32-40, wherein i) n is 2 and m is 2; or ii) n is 1 or 2; or iii) n is 1 and m is 2.

42. A compound having Structural Formula IV:



IV, or pharmaceutically acceptable salts thereof, wherein:



Het is a 5- to 6-membered heteroaryl;

R¹ is H, -CN, halogen, C₁-C₄ alkyl, -O-(C₃-C₅ cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C₁-C₄ alkyl), wherein when R¹ is not H, -CN or halogen, R¹ is optionally substituted with one or more halogens;

each R² is independently hydrogen, halogen or C₁-C₄ alkyl;

R³ is H or F;

R¹¹ is H or -CH₃;

R²¹ is H, halogen, C₁-C₄ alkyl, C₃-C₅ cycloalkyl or 4- to 6-membered heterocycle;

R²² is H, halogen or C₁-C₂ alkyl; and

R²⁴ is H, C₁-C₄ alkyl, -(C₁-C₄ alkyl)-OH, -(C₁-C₄ alkyl)-N(R²⁴¹)₂, -(C₁-C₄ alkyl)_t-O_u-(C₃-C₅


cycloalkyl), $-(C_1-C_4 \text{ alkyl})_t-O_u-(4\text{- to } 6\text{-membered heterocycle})$ or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$, wherein:

t is 0 or 1;

u is 0 or 1;

with the proviso that when u is 1, t is 1; and

R^{241} is H or C_1-C_2 alkyl.



44. The compound of claim 42 or 43, wherein i) R^1 is halogen, $-CN$ or C_1-C_2 haloalkyl; or ii) R^1 is $-CN$.

45. The compound of any of claims 42-44, wherein R^2 is H.

46. The compound of any of claims 42-45, wherein i) R^{21} is halogen, C_1-C_4 alkyl, C_3-C_5 cycloalkyl or 4- to 6-membered heterocycle; or ii) R^{21} is C_1-C_2 alkyl or C_3-C_5 cycloalkyl; or iii) R^{21} is C_1-C_2 alkyl; or iv) R^{21} is C_3-C_5 cycloalkyl.

47. The compound of any of claims 42-46, wherein i) R^{22} is H or C_1-C_2 alkyl; or ii) R^{22} is H; or iii) R^{22} is C_1-C_2 alkyl; or iv) R^{22} is $-CH_3$.

48. The compound of any of claims 42-47, wherein i) R^{24} is C_1-C_4 alkyl or $-(C_1-C_4 \text{ alkyl})-O-(C_1-C_4 \text{ alkyl})$; or ii) R^{24} is $-(C_1-C_2 \text{ alkyl})-O-(C_1-C_2 \text{ alkyl})$.

49. A pharmaceutical composition comprising any of the compounds of claims 1-48 and a pharmaceutically acceptable carrier, excipient, or diluent.

50. Use of a therapeutically effective amount of any of the compounds of claims 1-48 or a pharmaceutical composition of claim 49 in the manufacture of a medicament for treating a viral infection in a subject.

51. The use of claim 50, wherein the viral infection comprises hepatitis C infection.

52. Use of a therapeutically effective amount of any of the compounds of claims 1-48 or a pharmaceutical composition of claim 49 in the manufacture of a medicament for treating a metabolic disorder in a subject in need thereof.

53. Use of a therapeutically effective amount of any of the compounds of claims 1-48 or a pharmaceutical composition of claim 49 in the manufacture of a medicament for treating a cancer in a subject in need thereof.

54. The use of claim 53, wherein the cancer is breast cancer, pancreatic cancer, or colon cancer.

55. The use of claim 53, wherein the cancer is pancreatic cancer.